IMU Biosciences selects Waters to advance breakthrough AI immune mapping platform to transform early diagnosis, monitoring, and precision medicine. Jun 24, 2026, 08:00 ET * IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. * Waters Biosciences' technologies, including BD FACSDiscover(TM) and BD Rhapsody(TM) Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights. * Partnership supports IMU's expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling. MILFORD, Mass., June 24, 2026 /PRNewswire/ - Waters Corporation (NYSE: WAT) and IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform. The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies,[1] including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon(TM) Real Dyes, BD Rhapsody Instruments, and BD OMICS-One(TM) WTA Next Assay and Protein Panels, with IMU's HD analysis and proprietary AI and machine learning analytics, that can reproducibly characterize the immune system in real time, to turn complex immune data into insights at scale across discovery, translational, and clinical research applications. IMU measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample,[2] combining HD multiomic analysis with machine learning analytics. IMU is building the world's largest immune dataset,[3] with unrivaled access to patient samples and population-wide clinical data, establishing a universal standard for immune profiling. "Waters Biosciences was the clear partner to help IMU Biosciences scale our HD Immunology platform to the level required for true population-wide immune mapping, given their longstanding leadership in high-throughput flow cytometry and single-cell technologies," said John Baker, Ph.D., Chief Executive Officer, IMU Biosciences. "Our world-leading immune dataset and proprietary AI analytics will unlock the potential of Waters' best-in-class analytical instruments, accelerating our work to decode the immune system and power the next generation of precision medicine." Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation added, "By partnering with IMU Biosciences, we are helping to build the most detailed picture of the human immune system ever assembled at clinical scale. Together, our companies' cutting-edge technologies across instruments, reagents, and informatics will help advance immune profiling into a standardized, universally accessible clinical tool that can be used across the continuum of care for cancer and other diseases, supporting smarter, faster drug development." The companies intend to pursue additional studies in translational research for novel biomarker discovery to enable clinical applications in flow cytometry. Waters Biosciences and IMU Biosciences presented data at the annual meeting of the International Society for the Advancement of Cytometry (CYTO 2026), demonstrating system-level immune profiling on the BD FACSDiscover A8 Cell Analyzer with a 58-color spectral panel using BD reagents, and integration of high-throughput single-cell multiomics with the BD Rhapsody System. BD is a trademark of Becton, Dickinson and Company. Waters is a trademark of Waters Corporation or its affiliates. All other marks are the property of their respective owners. About Waters Corporation: Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about. The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: www.waters.com/bdtransaction. About IMU Biosciences: IMU Biosciences is decoding the immune system at unprecedented resolution, speed, and scale to pioneer a paradigm shift in how we understand, diagnose and treat disease. Founded by a leading team of experimental immunologists and computational biologists with over a decade of expertise from the Francis Crick Institute and King's College London - IMU is moving immune system analysis from a simplistic, fragmented view to a comprehensive, 'high definition' system. IMU uses a simple blood sample to measure the immune system in unprecedented detail, combining high-fidelity multi-omic analysis with proprietary machine learning analytics. IMU is building the world's largest immune dataset, with unrivalled access to patient samples and population-wide clinical data, and is establishing a universal standard for immune profiling to fuel discoveries, devise treatments, and empower clinicians. IMU is advancing its platform towards clinical application across a broad range of immune-mediated diseases and therapeutic contexts, with active programmes in stem cell and bone marrow transplantation, solid organ transplantation, and immuno-oncology. References: * All Waters products used in the partnership are research use only (RUO). * Sourced from IMU Biosciences Data: https://imubiosciences.com/our-science. * Sourced from IMU Biosciences Data: https://imubiosciences.com/our-science. Molly Gluck Head of External Communications Waters Corporation +1.508.498.9732 [email protected]

UK immune profiling biotech IMU Bio closes Series A extension at over USD 53m. June 2, 2026 London-based IMU Biosciences has closed an oversubscribed extension to its Series A financing round, bringing the total raise to over USD 53 million (GBP 40 million) as the company advances its immune profiling platform and expands its clinical programs. The IMU Biosciences Series A financing was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank, Meltwind, and existing investors. The round brings total capital raised by the company to USD 60 million. Proceeds will be directed toward operational expansion, clinical platform infrastructure, and the advancement of active programs in stem cell transplantation, solid organ transplantation, and immuno-oncology, including a UK research consortium called MANIFEST, which is investigating patient response to cancer immunotherapies. IMU was founded by experimental immunologists and computational biologists with backgrounds at the Francis Crick Institute and King's College London. The company's core technology combines high-fidelity multi-omic analysis with proprietary machine learning analytics, enabling the measurement of over 100 million immune data points from a single blood sample. The company said it has assembled what it describes as the world's largest immune dataset, now scaling to more than 25,000 individuals in 2026, built through access to patient samples and population-wide clinical data. IMU is positioning this dataset as the basis for a universal standard in immune profiling - one designed to support disease mechanism discovery, treatment monitoring, and patient-level prediction of therapeutic response. Active clinical programs span stem cell and bone marrow transplantation, solid organ transplantation, and the MANIFEST immuno-oncology consortium. The company said it is advancing its platform across immune-mediated diseases more broadly, though specific drug candidates or regulatory milestones were not disclosed in the announcement. The raise reflects continued investor interest in data-driven approaches to immunology, particularly platforms that aim to move beyond single-biomarker diagnostics toward system-level immune characterization. IMU's approach - aggregating multi-omic data at population scale and applying machine learning to derive clinically actionable outputs - sits within a broader industry effort to make immune profiling tractable at clinical scale. The company has not disclosed a timeline for commercialization or partnerships, and no regulatory submissions have been announced. With USD 60 million in total funding secured, IMU said it is focused on scaling its platform infrastructure and translating its dataset into clinical utility across transplantation and oncology settings. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/